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THERE is no doubt that ovarian neoplastic changes are produced in BALB/c
mice by the prolonged administration both of progesterone (P) and 19-nor-P, and
that the toxicity ofthe latter is about ten times that of progesterone. A detailed
description of these ovarian changes has been given in the preceding paper
(Lipschutz, Iglesias, Panasevich and Salinas, 1967). Since the contraceptives
used in women are 19-nor-derivatives it seemed advisable to extend our research
also on some of these contraceptives. The contraceptives studied in our work
with mice were: (1) 17ac-ethinyl-19-nor-testosterone (or norethindrone), and (2)
17Lx-ethinyl-A5'10-19-nor testosteronet (or norethynodrel), not combined with
oestrogen.
The incidence of neoplastic ovarian changes induced with norethindrone and
norethynodrel
Pellets containing 40 per cent ofthe contraceptive and 60 per cent ofcholesterol
were implanted subcutaneously into female mice 2 months old. Each animal
received 1 pellet. All the animals were housed with males. The 25 animals
with pellets ofnorethindrone were kept for 535 to 539 days to be necropsied at the
age of 596 to 608 days; the 24 animals with pellets ofnorethinodrel were kept for
524 to 568 days to be necropsied at the age of 583 to 649 days. The quantities
absorbed were determined for each of the animals separately, with the same
precautions as used with P and 19-nor-P. The average amounts absorbed were
7.7 ± 0*5 ,tg./day and 5-5 ± 0-2 ,tg./day.
There were 13 animals with ovarian neoplastic changes in the norethindrone
group, and 2 animals with ovarian tumours in the norethynodrel group. But in
each of the two groups absorption was the same in animals with and without
neoplastic ovarian changes (Table I):
TABLE I.-Absorption of Norethindrone and Norethynodrel
Number of Absorption Absorption, range
Group animals pg./day pg./day
Norethindrone
Total 24* . 7-7 0 5 . 3-6-15-9
With tumours 13 . 7-6 0 7 . 3 6-121
Notumours 11 . 7-8 1-6 . 3-6-15-9
Norethynodrel
Total 23* 55 0-2 . 4-5-8-0
With tumours 2 5-8 5-06-7
No tumours . 21 . 5-4 . 4-0-8-0
* Pellet not found at necropsy of 1 animal; without neoplastic changes.
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The incidence of neoplastic ovarian changes in the two groups is summarized
in Table II:
TABLE II.-Number of Animals with Ovarian Tumours
Number of animals
Steroid With With
used ,ug./day Total* growths growths
Norethindrone . 77 . 25 13 52*0
Norethynodrel . 5- 5 24 2 8- 3
* See also * of Table I. None ofthese animals had offsprings in the course
of the experiment.
There is, first, the fact that with an average ofonly 7-7 ,ug./day ofnorethindrone
the incidence was much greater than in animals receiving 59 to 117 ,ug./day of P
(see Table III of the preceding paper). The incidence with 7*7 ,ug./day of nore-
thindrone was coincident with that of 665 ,tg./day of P. The incidence with
7.7 ,ug./day of norethindrone was superior even to that of 15 /,g./day of 19-nor-P.
There is another fact of considerable interest. With an average of 15 jtg./day
of 19-nor-P there was among 33 animals only 1 animal with bilateral neoplastic
ovarian changes (see Fig. 1 of the previous paper).
TABLE III.-Classification of Ovarian Tumours
Number G
Steroid of animals G G G G G bilat. ±
used with G macro micro I micro II bilat. bifocal bifoc.
nor-drone . 13 2 . 4 . 7 . 4 . 5 3
nor-drel 2 . 2 . 0 . 0
G = Granulosa-cell tumour.
In experiments with 7.7 ,ug./day of norethindrone there were, as shown in
Table III, no less than 4 bilateral cases among 25 animals. It is a difference of
about five times. There were also 5 cases with bifocal growths, 3 of these com-
bined with bilateral growths, i.e. a greater abundance than with 665 ,ug./day of P.
With an average of 5-5 ,ug./day of norethinodrel there were 2 cases of macro-
tumours but not a single case with a microtumour (Tables II and III).
The microscopical structure of the ovarian growths induced by the two contraceptives
The microscopical structure ofthe macrotumours in animalswith norethindrone
and norethynodrel was fully coincident with that in animals with P or 19-nor-P.
This remains true also for most of the microtumours I and II induced by nore-
thindrone, including those with an index of only 0 1 or even less (Fig. 1; Fig.
2A, B).
It would seem that two different tissues are implicated in the structure of some
of these tumours (experiments with norethindrone, Fig. 2c, D, E; Fig. 3). The
cells of the additional type of tumorous tissue (Fig. 2D and 3B) are different both
from those ofthe typical granulosa-cell tumour (Fig. 2B) but also from the cells of
the follicular granulosa (Fig. 2E) and from those of the corpus luteum (Fig. 5).OVARIAN CHANGES INDUCED IN MICE BY CONTRACEPTIVES
The interest offered by the fact that two different types of tissues occur in experi-
mental microtumours is the greater as it occurs also in the granulosa-cell tumour
of women (see for instance Fig. 146a and b of Glasunov, 1961).
The overwhelming majority of microtumours, both of micro-I and micro-II,
occupied peripheral sites posing again the problem, as with P and 19-nor-P, of the
neoplastic proliferation of the germinal epithelium. But there were 2 cases in
which the site and the contours may be interpreted as denoting a follicular origin
(Fig. 4).
Another case (Fig. 5) also is of interest because of the simultaneous presence
of the following structures: (1) the typical tissue of the granulosa-cell tumour;
(2) identical neoplastic tissue but which by site and contours may suggest follicular
origin; (3) a corpus luteum which offers the opportunity to differentiate the
typical tissue of granulosa-cell tumours and that of corpora lutea.
The differential ovarian condition in experiments uwith norethindrone and nore-
thynodrel
As reported above the incidence of ovarian tumours is very different in
animals receiving norethynodrel from that in animals receiving norethindrone
(Tables II and III). It is not probable that the difference was due to the some-
what smaller amount ofnorethynodrel absorbed (Table 1). Among the 13 animals
with tumours in the norethindrone group there were 3 animals with tumours
though absorption was in these 3 animals of only 3.6 to 4.4 /1g./day, against ain
average of 5.5 /1g./day of norethynodrel. One was a macrotumour with an index
of about 20, induced by 4.4 /,g./day of norethindrone. The two others were
microtumours induced with 3.6 ,ug. and 3-9 /1g./day of norethindrone (Fig. 6).
Thus it seems justified to assume that the tumorigenic faculty of norethindrone
is probably superior to that of norethynodrel. In the 2 cases of macrotumours
with norethynodrel the absorption was of 5 0 and 6*7 ,tg./day.
It is of considerable interest that the whole ovarian condition induced by P,
on the one hand, and by each of the two contraceptives on the other, is different.





Age With corpora lutea With ovarian
Groul) ,zg./day days Total lutea 0/ tumours
Normal 0 621-655 . 33 8 24 1
Progesterone 290 617-624 44 0 0 1
Nor-drone . 7- 7 596-610 25 5 20 13
Nor-drel 55 616-649* . 24 16 67 2
* 1 animal 583 days only, without corpora lutea.
With an average of 7-7 /1g./day of norethindrone ovarian neoplastic growth is
induced in no less than 52 per cent of animals. But the percentage of animals
with corpora lutea, compared to normal animals of the same age, was scarcely
changed when 7-7 /1g./day of norethindrone were given. With 5-5 ,ug./day of
norethynodrel the percentage of animals with corpora lutea was even greatly
increased.
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Various authorities have studied the influence of norethynodrel on the ovary
of the rat (Pincus and Merrill, 1961, see Pincus, 1965, p. 5. Corpora lutea are
not consistently suppressed; they may be present in experiments lasting up to 86
days though the ovaries contain a smaller number of corpora lutea than in the
controls (Holmes and Mandl, 1926b). In experiments of shorter duration nore-
thynodrel caused enlargement of corporea lutea (Blaquier, 1964). Excessive
luteinization was stimulated in the remaining ovary after hemicastration of rats
when higher doses of norethynodrel were given (Petersen, Edgren and Jones,
1964). However, in rats which received large doses of norethynodrel during
100 days Lakshman and Nelson (1963) observed a marked decrease in ovarian
weight. When the drug was administered for 100 days and the animals killed
50 days later the ovarian weight was restored and the average number of corpora
lutea per animal was greater than in normal animals. Lakshman and Nelson
speak of a ' rebound effect ". In guinea-pigs the great development of corpora
lutea in the intrasplenic graft offered a good opportunity for the study of the
antiluteinizing activity of steroids (Mardones, Iglesias and Lipschutz, 1956;
Lipschutz, 1956; Lipschutz and Iglesias, 1961). When large quantities of nore-
thynodrel are given during 90 days corpora lutea are suppressed; when the
animals are killed 30 to 110 days after the treatment there is a " rebound effect "
(Haller, 1963). Our Table IV shows, as already insisted upon, that in mice with
the prolonged administration of sterilizing doses of norethindrone the number of
animals with corpora lutea scarcely undergoes any change; with the prolonged
administration of sterilizing doses of norethynodrel the number of animals with
corpora lutea greatly increases, similarly to the " rebound effect " as observed in
rats under somewhat different experimental conditions.
Thus results as summarized in our Tables fI and IV leave no doubt that the
tumorigenic action of a gestagen is not necessarily related to its antiluteinizing
capacity. The quantity of 7-7 ,ag./day norethindrone is probably devoid of any
antiluteinizing faculty; but this quantity is already tumorigenic-there were
2 animals with corpora lutea which had also ovarian tumours. The quantity of
29/tg./day of P is definitely antiluteinizing but the tumorigenic faculty of this
amount is scarcely significant when compared with normal animals of this strain
of mice. With an average of 5.5 ,ug./day of norethynodrel the percentage of aged
EXPLANATION OF PLATES
FIG. 1.-Bilateral. 535 days, 12 1ig./day of norethindrone (9360). 2 micro-I G. Index:
0-06 and 0 3. The latter is shown: A, x 47. B, x 310.
FIG. 2. Bilateral and bifocal. 538 days, 9-5 ,g./day of norethindrone 9335). 3 micro-II G.
Index: (a) 0-1; (b) 0-1 and (c) 0-2. The 2 latter are shown. (b) A, X 121. B, x 310. (C)
c, x 121. D, x 310. E, x 310. Part offollicle; note the difference of the tumour cells and
the follicular cells.
FIG. 3.-Bilateral. 539 days, 8-5 ,ug./day of norethindione (9293). 1 macro and 1 micro-I
G. Index: 6 and 0-8. The latter is shown. A, x47. B, x310. c, X 310. Identical
with 2oD.
FIG. 4. Bifocal. 597 days, 8 ,ug./day of norethindrone (9367). 2 micro-Il G. Index: 022
and 0-3. A, x 47. The two foci are seen. B, X 310. Focus of follicular origin.
FIG. 5.--Nlonofocal. 537 days, 6 ,ug./day of norethindrone (9315). 1 micro-I G. Index:
1-3. A, X47. B, x47. On the left: Corpus luteum, to the right the tumour. Pait of the
tumour seemingly of follicular origin.
FIG. 6. Monofocal. 539 days, 3 9 ,ug./day of norethindrone (9322). "Micro-I G. Index:
0-4. A, X 47. B, x 310.
FIG. 7.--Large ovarian cyst. 567 days, 4 ,Ig./day of norethynodrel (91-72). x 9.BarrisH JOURNAL OF CANCER.
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animals with corpora lutea was greatly increased. However, though highly
luteinizing, norethynodrel has a pronounced tumorigenic action (2 macrotumours!).
One of the two animals receiving norethynodrel and showing a macrotumour had
corpora lutea.
The above experimental statements as summarized in Table IV put us face
to face with the significant fact that the various gestagens differ as totheiractivities
not only quantitatively but also as to their mode of action.
There is still another striking difference between norethindrone and nore-
thynodrel which corroborate the above conclusion. There were in the group of
24 animals with norethynodrel no less than 9 animals with large ovarian cysts
(Fig. 7), most probably of the rete. On the contrary, in the group of 25 animals
with norethindrone there were but 2 animals with similar cysts.
DISCUSSION
The prolonged administration of P, 19-nor-P and two 19-nor-steroids used in
women as contraceptives provides the opportunity to study various new aspects
of the tumorigenic action of these compounds on the ovary.
All the mentioned progestational steroids when administered continuously to
BALB/c mice cause ovarian tumours. These tumours are always granulosa-cell
tumours varying structurally only in some details and varying greatly in size.
But there is full identity as to the site of origin of these ovarian tumours: they
occupy in the overwhelming number of cases a peripheral site of the ovary,
putting us face to face before the question whether there is a neoplastic prolifera-
tion of the germinal epithelium. In some tumours elicited by norethindrone
follicles were seemingly also implicated in the origin of the tumour (Fig. 4A and
Fig. 5B).
However, notwithstanding this identity of origin and evolution of the tumours
elicited by the different steroids mentioned, the condition of the ovary outside
the tumour is in no way similar in all the cases in which a tumour arises. With
tumorigenic quantities of P corpora lutea are always absent; in animals of the
same age receiving tumorigenic quantities ofnorethindrone the number of animals
with corpora lutea remains the same as in normal animals of that age; with
tumorigenic quantities of norethynodrel the number of animals with corpora
lutea increases greatly. Thus there can be no doubt that the antiluteinizing and
tumorigenic ovariotropic faculty of a steroid are not necessarily related one to the
other. But here another intricate question arises. As generally assumed the
steroid exercises its antiluteinizing faculty via the neuro-hypophyseal axis.
Does the disparity between the antiluteinizing and tumorigenic faculty of a
steroid mean that the tumorigenic action of this steroid is exercised by a direct
ovariotropic action? Or does this disparity mean that the differential ovarian
aspects resulting under the influence of P, on one hand, of norethindrone and
norethynodrel, on the other. are the outcome of differential neurohypophyseal
conditions induced by the interference of these different steroids?
The fact that there are differences in the results obtained with the two 19-nor-
contraceptives we used in our work norethynodrel, contrary to norethindrone,
causes an abundance of ovarian cysts-is rather in favour of the concept of
differential neurohypophyseal imbalances. The microscopical and functional
condition of the hypophysis in animals treated with norethynodrel has been
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studied by various authorities (Holmes and Mandl, 1962b; Lakshman and Nelson.
1963; Saunders, 1964). But the notion of differential neurohypophyseal
imbalances as applied to tumorigenesis derives from new knowledge about the
evolution of tumours in ovarian grafts.
There is a divergent neoplastic reaction of intrasplenic, intrahepatic and
intrarenal ovarian grafts which cannot be explained otherwise than by the concept
of differential functional imbalances of the hypophysis (Lipschutz, Panasevich,
Cerisola and Alvarez, 1964; Lipschutz, Panasevich and Alvarez, 1964). Likewise,
the comparative neoplastic reaction of an intrasplenic ovarian graft, on one hand,
and an ovarian remnant in situ after partial or subtotal castration in mice, on the
other hand, cannot be explained but by recurring to differential hypophyseal
imbalances being here in play: the granulosa-cell tumour arises in intrasplenic
ovarian grafts in mice in about 10 months, whereas in the ovarian remnant after
partial castration in the same strain of mice there is even at 17 months mostly
luteoma and a scarce beginning of G (Lipschutz, 1960).
One of the most impressive findings was for us the differential evolutional
pattern of the ovarian granulosa-cell tumour in the intrasplenic graft, on one
hand, and in the ovary in situ under the influence of various steroids on the other
hand (see discussion in the preceding paper). So far the assumption that this
differential neoplastic evolution is due to adifferentialneuro-hypophyseal constella-
tion would be the most acceptable.
It cannot be our purpose to discuss the question whether, or how far, our
findings are applicable to the clinical use of 19-nor-contraceptives. First there
is the fact that the pathological pattern of reaction to steroids in general varies
from one species to the other. Besides this the duration of our experiments of
13 to 18 months corresponds to about 30 to 45 years in humans. However, we
ully agree with Dodds (1961), Holmes and Mandl (1962a) and Charles (1964) who
have attracted attention to the question of possible dangers from the prolonged
use of 19-nor-contraceptives.
SUMMARY
Ovarian granulosa-cell tumours are elicited in mice by the prolonged admiinis-
tration of norethindrone and norethynodrel.
Large tumours may occur; but the growths are mostly microtumours though
structurally identical with the large tumours.
The neoplastic faculty of the two synthetic 19-nor-steroids is greatly superior
to that of progesterone.
The neoplastic faculty of the mentioned steroids is not concomitant with an
antiluteinizing one. Though such a coincidence is suggested by progesterone it
is not the case with norethindrone or norethynodrel.
With norethynodrel ovarian cysts, probably of the rete, are also elicited.
The differential evolutional pattern of the granulosa-cell tumour in ovarian
grafts, on one hand, and of the granulosa-cell tumour induced by steroids, on the
other, cannot be explained otherwise than by assuming that differential functional
imbalances ofthe neuro-hypophyseal axis are in play. This assumption is justified
even when comparing the differential results obtained by the prolonged adminis-
tration of norethynodrel with those obtained with norethindrone.
It would be daring to draw any conclusions as to the toxicity ofthe mentioned
steroids in humans. The 18 months of treatment in mice correspond to aboutOVARIAN CHANGES INDUCED IN MICE BY CONTRACEPTIVES 159
45 years in women. The administration of the steroids was in our experimental
work a continuous one whereas the clinical use offers the possibility of a discon-
tinuous administration.
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Parke, Davis & Co. who was kind enough to examine several of our microscopical
preparations; and as always to our histological, photographical, biochemical and
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